StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Thursday. The firm issued a buy rating on the biotechnology company’s ...

January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will ...

Every investor in Adaptimmune Therapeutics plc (NASDAQ:ADAP) should be aware of the most powerful shareholder groups. We can see that retail investors own the lion's share in the company with 50% ...